

Reference:	FOI.15930.24
Subject:	Treatment of Multiple Myeloma
Date of Request:	11 November 2024

Requested:

1. Over the past 6 months, how many adult multiple myeloma [MM] patients have you treated? If you refer your multiple myeloma patients to another centre, please state which.
2. Of the multiple myeloma patients over the past 6 month, how many were treated with the following:
 - Bortezomib [Velcade], Melphalan/Cyclophosphamide and prednisolone/dexamethasone (VMp or VCd)
 - Bortezomib, thalidomide and dexamethasone [VTD]
 - Daratumumab [Darzalex] with Lenalidomide [Revlimid] and dexamethasone
 - Daratumumab [Darzalex], Bortezomib [Velcade], thalidomide and dexamethasone (known as Dara-VTd)
 - Selinexor, Bortezomib [Velcade] and dexamethasone
 - Carfilzomib [Kyprolis] and dexamethasone
 - Bortezomib [Velcade] monotherapy or with dexamethasone
 - Daratumumab [Darzalex], Bortezomib [Velcade] and dexamethasone (known as DVd or DBd)
 - Carfilzomib [Kyprolis], Lenalidomide [Revlimid] and dexamethasone
 - Belantamab Mafodotin [Blenrep]
 - Idecabtagene vicleucel [Abecma]
 - Isatuximab [Sarclisa], Pomalidomide [Imnovid] and dexamethasone (known as IsaPd)
 - Elranatamab
 - Daratumumab [Darzalex] monotherapy
 - Ixazomib [Ninlaro], Lenalidomide [Revlimid] and dexamethasone (known as IRd)
 - Lenalidomide [Revlimid] and dexamethasone
 - Lenalidomide [Revlimid] monotherapy
 - Pomalidomide [Imnovid] and dexamethasone
 - Selinexor and dexamethasone
 - Talquetamab
 - Teclistamab [Tecvayli]
 - Any other systemic anti-cancer therapy

Response:

1. Hywel Dda University Health Board (UHB) has treated one hundred and thirty-six (136) patients diagnosed with Multiple Myeloma between 1 May 2024 and 31 October 2024.
2. The table below provides the number of patients diagnosed with Multiple Myeloma that were treated with each of the named treatments, between 1 May 2024 and 31 October 2024.

Treatments	Patients
Belantamab Mafodotin [Blenrep]	*
Bortezomib [Velcade] monotherapy or with dexamethasone	0
Bortezomib [Velcade], Thalidomide and Dexamethasone [known as VTD]	0
Bortezomib [Velcade], Cyclophosphamide/Melphalan and Dexamethasone/Prednisolone [known as VCD or VMP]	5
Carfilzomib [Kyprolis] and Dexamethasone	0
Carfilzomib [Kyprolis], Lenalidomide [Revlimid], and Dexamethasone [known as KRd]	7
Daratumumab [Darzalex] monotherapy	26
Daratumumab [Darzalex], Bortezomib [Velcade] and dexamethasone (known as DVd or DBd)	*
Daratumumab [Darzalex], Velcade [Bortezomib], Thalidomide and Dexamethasone [known as Dara-VTd]	13
Daratumumab [Darzalex] with Lenalidomide [Revlimid] and dexamethasone	11
Elranatamab	0
Idecabtagene vicleucel [Abecma]	0
Isatuximab [Sarclisa], Pomalidomide [Imnovid] and Dexamethasone [known as IsaPd]	9
Ixazomib [Ninlaro], Lenalidomide [Revlimid] and Dexamethasone [known as IRd]	5
Lenalidomide [Revlimid] monotherapy	24
Lenalidomide [Revlimid] and Dexamethasone	23
Pomalidomide [Imnovid] and Dexamethasone	*
Selinexor, Bortezomib [Velcade] and dexamethasone	0
Selinexor and dexamethasone	0
Talquetamab	0
Teclistamab [Tecvayli]	0
Any other systemic anti-cancer treatment	*

Where the figures in the table have been replaced with an asterisk (*), the UHB is unable to provide you with the exact number of patients due to the low numbers of cases (less than 5), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000 (FOIA). This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations, as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.